Moderna, the pioneer in mRNA technology, is at a critical juncture. The company's stock advances amid market declines, displaying resilience. However, it's experiencing some backlashes. The HHS (Health and Human Services) has cancelled $766 million in contracts due to misgivings about the 'under-tested' mRNA technology, including concerns around rare heart side effects. The
US FDA, whilst approving
Moderna's next-generation COVID vaccine for older adults, also requested a wider age range for heart risk warnings. The company has submitted an updated COVID vaccine for review and is making significant strides in developing additional vaccines, despite reduced government funding. This includes a potential flu vaccine, which is under FDA scrutiny over a reported case of Guillain-Barré syndrome. While there are growing safety concerns and regulatory hurdles,
Moderna continues to innovate, developing vaccines for various infectious diseases and even cancer. The company's
mRNA medicines course empowers a new generation of researchers and exciting developments in mRNA technology are expected.
Moderna MRNA News Analytics from Thu, 05 Sep 2024 07:00:00 GMT to Fri, 20 Jun 2025 21:50:05 GMT -
Rating -3
- Innovation 5
- Information 8
- Rumor -2
